150 related articles for article (PubMed ID: 31988076)
1. The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma.
Lee HJ; Pham T; Chang MT; Barnes D; Cai AG; Noubade R; Totpal K; Chen X; Tran C; Hagenbeek T; Wu X; Eastham-Anderson J; Tao J; Lee W; Bastian BC; Carbone M; Webster JD; Dey A
Cancer Res; 2020 Apr; 80(8):1656-1668. PubMed ID: 31988076
[TBL] [Abstract][Full Text] [Related]
2. Loss of BAP1 Leads to More YAPing in Pancreatic Cancer.
Brekken RA
Cancer Res; 2020 Apr; 80(8):1624-1625. PubMed ID: 32295782
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
4. Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.
Tayao M; Andrici J; Farzin M; Clarkson A; Sioson L; Watson N; Chua TC; Sztynda T; Samra JS; Gill AJ
PLoS One; 2016; 11(3):e0150338. PubMed ID: 26982343
[TBL] [Abstract][Full Text] [Related]
5. BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice.
Perkail S; Andricovich J; Kai Y; Tzatsos A
Nat Commun; 2020 Jun; 11(1):3018. PubMed ID: 32541668
[TBL] [Abstract][Full Text] [Related]
6. BAP1 regulates AMPK-mTOR signalling pathway through deubiquitinating and stabilizing tumour-suppressor LKB1.
Yang C; Ding H; Yang Y; Yang L; Yang Y; Fang M; Ren J; Hu R; Wang C; Geng W
Biochem Biophys Res Commun; 2020 Sep; 529(4):1025-1032. PubMed ID: 32819560
[TBL] [Abstract][Full Text] [Related]
7. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.
Carbone M; Ferris LK; Baumann F; Napolitano A; Lum CA; Flores EG; Gaudino G; Powers A; Bryant-Greenwood P; Krausz T; Hyjek E; Tate R; Friedberg J; Weigel T; Pass HI; Yang H
J Transl Med; 2012 Aug; 10():179. PubMed ID: 22935333
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Ventii KH; Devi NS; Friedrich KL; Chernova TA; Tighiouart M; Van Meir EG; Wilkinson KD
Cancer Res; 2008 Sep; 68(17):6953-62. PubMed ID: 18757409
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
[TBL] [Abstract][Full Text] [Related]
10. Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome.
Louw A; Creaney J; Thomas A; Van Vliet C; Harvey NT; Wood BA; Mesbah Ardakani N
Am J Dermatopathol; 2020 Nov; 42(11):872-875. PubMed ID: 32649346
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma.
Webster JD; Pham TH; Wu X; Hughes NW; Li Z; Totpal K; Lee HJ; Calses PC; Chaurushiya MS; Stawiski EW; Modrusan Z; Chang MT; Tran C; Lee WP; Chalasani S; Hung J; Sharma N; Chan S; Hotzel K; Talevich E; Shain A; Xu M; Lill J; Dixit VM; Bastian BC; Dey A
Pigment Cell Melanoma Res; 2019 Mar; 32(2):269-279. PubMed ID: 30156010
[TBL] [Abstract][Full Text] [Related]
12. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
13. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
14. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage.
Eletr ZM; Yin L; Wilkinson KD
FEBS Lett; 2013 Dec; 587(24):3906-11. PubMed ID: 24211834
[TBL] [Abstract][Full Text] [Related]
15. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
Marušić Z; Buljan M; Busam KJ
J Cutan Pathol; 2015 Jun; 42(6):406-12. PubMed ID: 25902915
[TBL] [Abstract][Full Text] [Related]
16. The Hippo Pathway as a Driver of Select Human Cancers.
Kulkarni A; Chang MT; Vissers JHA; Dey A; Harvey KF
Trends Cancer; 2020 Sep; 6(9):781-796. PubMed ID: 32446746
[TBL] [Abstract][Full Text] [Related]
17. Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Fukuda T; Tsuruga T; Kuroda T; Nishikawa H; Ohta T
Curr Cancer Drug Targets; 2016; 16(2):101-9. PubMed ID: 26517537
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
19. Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Kadariya Y; Cheung M; Xu J; Pei J; Sementino E; Menges CW; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
Cancer Res; 2016 May; 76(9):2836-44. PubMed ID: 26896281
[TBL] [Abstract][Full Text] [Related]
20. Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
Owen D; Sheffield BS; Ionescu D; Churg A
Hum Pathol; 2017 Feb; 60():82-85. PubMed ID: 27984124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
